Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Noxopharm Ltd. ( (AU:NOX) ) has provided an announcement.
Noxopharm Limited has announced significant progress in its quarterly activities, including a follow-on Material Transfer Agreement with an international company, highlighting growing interest in its Sofra technology platform. The company also reported that its novel drug candidate, SOF-SKN™, successfully passed preclinical tests, paving the way for a clinical trial aimed at treating autoimmune diseases like lupus. These developments position Noxopharm to capitalize on the expanding global RNA market and strengthen its industry standing.
More about Noxopharm Ltd.
Noxopharm Limited is an Australian drug development company focused on creating innovative treatments for autoimmune diseases and leveraging its Sofra technology platform for vaccines and therapeutics. The company is actively involved in collaborations with international partners and research institutes to expand its market presence.
YTD Price Performance: -14.44%
Average Trading Volume: 93,652
Technical Sentiment Signal: Buy
Current Market Cap: A$22.5M
Learn more about NOX stock on TipRanks’ Stock Analysis page.